Related Experiment Video
Updated: Jun 16, 2025
12:13
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer
Annika Kohvakka1, Mina Sattari1, Janika Nättinen2
1Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, 33520, Tampere, Finland.
Cancer Gene Therapy
|August 15, 2024
Summary
This study reveals EPCART, a long noncoding RNA (lncRNA), regulates protein translation in prostate cancer (PCa) by influencing the PI3K/AKT/mTORC1 pathway. Reduced EPCART increases PDCD4, impacting PCa progression.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, with many functioning in the cytoplasm to modulate translation.
- The specific functions of numerous cancer-associated lncRNAs remain largely uncharacterized.
- Prostate cancer (PCa) presents a significant clinical challenge, necessitating a deeper understanding of its molecular underpinnings.
Purpose of the Study:
- To elucidate the molecular identity and functional role of EPCART, a previously identified potential oncogene in prostate cancer.
- To investigate how EPCART influences the translational machinery within prostate cancer cells.
- To explore the therapeutic and prognostic potential of EPCART and its associated pathways.
Main Methods:
- In silico analysis to determine the transcript structure and confirm EPCART as a non-peptide-coding lncRNA.
- Pathway analysis of differentially expressed genes in EPCART knockout cells.
- Quantitative proteome analysis to identify protein changes upon EPCART modulation.
- Investigation of signaling pathways, including PI3K/AKT/mTORC1, following EPCART manipulation.
Main Results:
- EPCART was confirmed as a non-peptide-coding lncRNA primarily localized in the cytoplasm at translation sites.
- EPCART knockout cells exhibited altered translational machinery, with increased levels of PDCD4, a translation inhibitor.
- EPCART silencing led to reduced AKT activation and mTORC1 pathway inhibition, impacting overall protein translation.
- PDCD4 was identified as a key mediator in EPCART's translational control.
Conclusions:
- EPCART functions as a translation-associated lncRNA in prostate cancer cells.
- EPCART modulates protein translation through the PI3K/AKT/mTORC1 signaling pathway.
- EPCART and PDCD4 hold potential as prognostic biomarkers in prostate cancer.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K